Clinical studies carried out at prestigious centres endorse the effectiveness of KALSIS® in the regulation of bone metabolism.
Clinical study of KALSIS® as a monotherapy for 6 months
in patients with osteopenia
Gailezers Clinical Hospital (Riga / LATVIA)
Dr. Med. Inese Legzdina, Vice President of the Latvian Osteoporosis Society.
RESULTS
KALSIS® is appropriate for the treatment of osteopenia, producing a rapid clinical effect.
An increase in bone density is observed, which would appear to halt the initial
process of osteoporosis and have an anabolic effect on bone tissue.
Patients divided into groups according to osteodensitometric result and relative average change on the osteopenic scale
negative dynamics
without change
positive dynamics
Prospective clinical study in patients with osteoporosis and bone pain
who had already received other monotherapies or combined therapies
(calcium supplements and analgesics or specific bone resorption inhibitors
- alendronate - and analgesics), with persistence of pain.
The patients received KALSIS® as a monotherapy for three months.
San Jorge Hospital (Tegucigalpa / HONDURAS) Dr. Daniel Dávila Nolasco
RESULTS
Reduction in frequency and intesity of pain.
In 84.78%, total improvement and good quality of life.
In 8.69%, partial improvement due to work overload.
